• Explore /
  • Poster
  • / Three-year follow-up data from KEYNOTE-966: Pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) compared with gem/cis alone for patients (pts) with advanced biliary tract cancer (BTC).

Three-year follow-up data from KEYNOTE-966: Pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) compared with gem/cis alone for patients (pts) with advanced biliary tract cancer (BTC).

Abstract Poster

Authors

null

Richard S. Finn

University of California, Los Angeles, Los Angeles, CA

Richard S. Finn , Makoto Ueno , Changhoon Yoo , Zhenggang Ren , Junji Furuse , Robin Kate Kelley , Stephen Lam Chan , Julien Edeline , Heinz-Josef Klümpen , Thomas Yau , Chris Verslype , Masato Ozaka , Mohamed Bouattour , Joon Oh Park , Arndt Vogel , Juan W. Valle , Li Yu , Usha Malhotra , Abby B. Siegel , Shukui Qin

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Hepatobiliary Cancer - Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT04003636

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 4093)

DOI

10.1200/JCO.2024.42.16_suppl.4093

Abstract #

4093

Poster Bd #

73

Abstract Disclosures